VACCINEX INC
NASDAQ: VCNX (Vaccinex, Inc.)
Kemas kini terakhir: 1 jam lalu1.29
0.46 (55.87%)
| Penutupan Terdahulu | 0.828 |
| Buka | 1.10 |
| Jumlah Dagangan | 610 |
| Purata Dagangan (3B) | 1,754 |
| Modal Pasaran | 3,452,861 |
| Harga / Jualan (P/S) | 3.04 |
| Harga / Buku (P/B) | 7.34 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,590.14% |
| EPS Cair (TTM) | -8.88 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 160.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.97% |
| Nisbah Semasa (MRQ) | 0.500 |
| Aliran Tunai Operasi (OCF TTM) | -16.19 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.54 M |
| Pulangan Atas Aset (ROA TTM) | -376.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -759.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Vaccinex, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -1.00 |
|
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.51% |
| % Dimiliki oleh Institusi | 45.01% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |